Expertise in
29
conditions

Dr. Victor Y. Yazbeck

Oncology
Virginia Commonwealth University Health System Authority
1300 E Marshall St, 
Richmond, VA 
Accepting New Patients
Offers Telehealth
Expertise in
29
conditions
Virginia Commonwealth University Health System Authority
1300 E Marshall St, 
Richmond, VA 

Overview

Victor Yazbeck is an Oncologist practicing medicine in Richmond, Virginia.

Dr. Yazbeck is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Splenectomy.

He is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 8 clinical trials. Dr. Yazbeck is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in VA

Hospital Affiliations

Medical College Of Virginia Hospitals
Henrico Doctors' Hospital
Cjw Medical Center
Vcu Health Tappahannock Hospital

Languages Spoken

English
Arabic
French

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Virginia Commonwealth University Health System Authority
1300 E Marshall St, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
Enrollment Status: Completed
Publish Date: August 13, 2026
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Study Phase: Phase 2
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
View 5 Less Clinical Trials

27 Total Publications

Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study.
Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study.
Journal: Blood advances
Published: November 17, 2025
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

VCU Health System Stony Point

9000 Stony Point Pkwy, 
Richmond, VA 
 (7.6 miles away)
804-327-3055
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Renato Martins is an Oncologist practicing medicine in Richmond, Virginia. Dr. Martins is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Salivary Gland Tumors, and Small Cell Lung Cancer (SCLC). Dr. Martins is currently accepting new patients.

Expertise in
30
conditions
Dr. Sosipatros A. Boikos
Hematology | Oncology
Expertise in
30
conditions
Dr. Sosipatros A. Boikos
Hematology | Oncology
Referral may be required

Virginia Commonwealth University Health System Authority

1250 E Marshall St, 
Richmond, VA 
 (0.1 miles away)
804-828-7999
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Sosipatros Boikos is a Hematologist and an Oncologist practicing medicine in Richmond, Virginia. Dr. Boikos is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Synovial Sarcoma, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Boikos is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Women's Cancer & Wellness Institute

1401 Johnston Willis Drive, Suite 1100, 
North Chesterfield, VA 
 (7.6 miles away)
804-323-5040
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Randal West is an Oncologist practicing medicine in North Chesterfield, Virginia. Dr. West is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Gastrostomy. Dr. West is board certified in (Obstetrics & Gynecology, Gynecology), American Board Of Obstetrics & Gynecology, and (Obstetrics & Gynecology). Dr. West is currently accepting new patients.

Frequently Asked Questions about Dr. Victor Y. Yazbeck

How do I make an appointment with Dr. Victor Y. Yazbeck?

You can book an appointment with Dr. Victor Y. Yazbeck by calling their office at 804-828-7999. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Victor Y. Yazbeck a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Victor Y. Yazbeck is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Victor Y. Yazbeck specialize in?

While Dr. Victor Y. Yazbeck is a Oncology, they have specific expertise in Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Victor Y. Yazbeck participate in research or clinical trials?

Yes. Dr. Victor Y. Yazbeck has published 27 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Victor Y. Yazbeck's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Victor Y. Yazbeck accept my insurance?

Dr. Victor Y. Yazbeck accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 804-828-7999 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yazbeck's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 20 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile